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ABSTRACT
Rapamycin is a naturally occurring macrolide whose
target is at the core of nutrient and stress reg-
ulation in a wide range of species. Despite well-
established roles as an inhibitor of cap-dependent
mRNA translation, relatively little is known about its
effects on other modes of RNA processing. Here,
we characterize the landscape of rapamycin-induced
post-transcriptional gene regulation. Transcriptome
analysis of rapamycin-treated cells reveals genome-
wide changes in alternative mRNA splicing and pro-
nounced changes in NMD-sensitive isoforms. We
demonstrate that despite well-documented attenua-
tion of cap-dependent mRNA translation, rapamycin
can augment NMD of certain transcripts. Rapamycin-
treatment significantly reduces the levels of both
endogenous and exogenous Premature Termina-
tion Codon (PTC)-containing mRNA isoforms and
its effects are dose-, UPF1- and 4EBP-dependent.
The PTC-containing SRSF6 transcript exhibits a
shorter half-life upon rapamycin-treatment as com-
pared to the non-PTC isoform. Rapamycin-treatment
also causes depletion of PTC-containing mRNA iso-
forms from polyribosomes, underscoring the func-
tional relationship between translation and NMD. En-
hanced NMD activity also correlates with an enrich-
ment of the nuclear Cap Binding Complex (CBC) in
rapamycin-treated cells. Our data demonstrate that
rapamycin modulates global RNA homeostasis by
NMD.
INTRODUCTION
Nonsense Mediated Decay (NMD) is a conserved RNA
surveillance system which recognizes and eliminates tran-
scripts containing Premature Termination Codons (PTCs)
(1). The NMD system prevents the synthesis of potentially
toxic proteins arising from transcripts containing nonsense
mutations, frame shifts and those generated by alternative
splicing. NMD is known to regulate the expression of many
genes, including those involved in the NMD pathway itself
(2,3).
The constellation of proteins associated with RNA tran-
scripts is dynamic and reflects the diverse cellular land-
scapes traversed by the mRNA. Virtually all human genes
undergo alternative splicing generating different mRNA
isoforms (4). All newly synthesized and spliced mRNAs
are bound by the nuclear Cap Binding Complex (CBC),
the Exon Junction Complex (EJC) and the nuclear poly(A)
binding protein (PABPN1) (5–7). By contrast, mRNAs en-
gaged in steady-state translation are depleted of EJC pro-
teins, and have exchanged CBC and PABPN1 at the cap and
poly(A) tail for the eukaryotic translation initiation factor
4E (eIF4E) and the cytoplasmic poly(A) binding protein
(PABPC), respectively (7–9). Termination codons located
more than 50–55 nt upstream from an Exon Junction Com-
plex (EJC) are strong NMD signals (10). During mRNA
processing, the SURF complex (SMG1, UPF1, eRF1 and
eRF3) associates with the downstream EJC and triggers
SMG1-dependent phosphorylation of UPF1, which is re-
quired for inhibition of translation initiation and subse-
quent nucleolytic decay of the targetedmRNA (11–13). Ad-
ditionally, shorter 3′UTRs are thought to suppress NMD
and presence of cis-acting elements in long 3′UTRs can trig-
ger NMD evasion (14,15).
NMDefficiencymay be linked to the composition ofmes-
senger ribonucleoprotein particles (mRNPs), from those ac-
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quired during splicing to the cap-binding factors. The CBC
is displaced by eIF4E in a translation-independent man-
ner (9,16). This exchange mechanism is driven by interac-
tions of CBP80 with the nuclear import receptor Importin
 (IMPb) (9). It is possible that this exchange may also be
regulated by mass action due to the high cytoplasmic con-
centrations of eIF4E (17). These rearrangements have im-
portant consequences for NMD; for example the interac-
tion of CBC with UPF1 promotes assembly of the SURF
complex and is important for activating NMD (18).
The mechanistic Target of Rapamycin Complex 1
(mTORC1) is central to the cellular nutrient/stress sens-
ing pathway and is inhibited by the naturally occurring
macrolide rapamycin, which promotes autophagy and ex-
tends lifespan in a number of species including yeast,
worms, flies and mammals (19,20). One important branch
of the mTORC1 signaling pathway modulates initiation of
cap-dependent translation through phosphorylation of tar-
gets such as 4EBPs (eIF4E-Binding proteins) and S6K1 (Ri-
bosomal Protein S6Kinase B1). The 4EBP family functions
as inhibitor of cap dependent translation by inducing nu-
clear sequestration of eIF4E (17). Active mTORC1 phos-
phorylates 4EBPs and counteracts their inhibitory effects
on eIF4E (21) thereby stimulating translation. In addition
to regulating the translation of messages bound by the cy-
toplasmic cap, mTORC1 also promotes the translation of
CBC-bound transcripts (22). Given that NMD and trans-
lation are functionally linked in mammalian cells (9,23), in-
hibitors of cap-dependent translations such as rapamycin
are predicted to inhibit NMD.
Here, we characterize the landscape of rapamycin-
induced post-transcriptional gene regulation in HEK 293
cells. Exposure of cells to either rapamycin or the trans-
lation elongation inhibitor emetine induced a pattern of
similar effects on genome-wide alternative splicing. Our
results demonstrate that rapamycin modulates NMD. As
expected we observed rapamycin-dependent inhibition of
NMD. However, we also made the surprising observation
that a proportion of established NMD isoforms were de-
pleted after rapamycin treatment.We studied a subset of en-
dogenous and exogenous PTC-containingmRNA isoforms,
and demonstrated that rapamycin enhances the efficiency
of NMD in a dose-, UPF1- and 4EBP-dependent man-
ner. Moreover, we found that PTC-containing mRNA iso-
forms accumulate in polyribosomes when mTORC1 is ac-
tive, but are depleted when cells are treated with rapamycin.
Because rapamycin-treatment induces nuclear accumula-
tion of eIF4E, we investigated the rapamycin-dependent
dynamics of CBC- and eIF4E-cap binding. We observed
the expected rapamycin-dependent nuclear accumulation
of eIF4E, and consequent depletion of eIF4E from cy-
tosolic mRNPs. Interestingly, we also found that CBC-
association with cytosolic mRNPs moderately increased
with rapamycin, suggesting accumulation of pioneer-like
mRNPs that may facilitate NMD. Taken together, our re-
sults demonstrate that mammalian cells can dynamically
regulate NMD efficiency of messenger RNA associated
with polyribosomes depending on cellular need.
MATERIALS AND METHODS
Cell culture and rapamycin treatment
Human Embryonic Kidney (HEK) 293 T cells were cul-
tured in DMEM 10% FBS (Santa Cruz Biotech) at 37◦C
5% CO2. For rapamycin (Cell Signaling) experiments, cells
were starved for 24 h in Glutamine deficient media DMEM
10%FBS. Following this, they were incubated in 22 nM ra-
pamycin or vehicle (DMSO) for 30min prior to feedingwith
complete medium containing DMSO or rapamycin. For
polyribosome experiments, cells were harvested 8 h-post ra-
pamycin stimulation. For dose-response assays and RNA-
seq cells were harvested 72 h at the indicated concentrations
diluted in vehicle (DMSO). 5 mg/ml of actinomycin D was
added after 48 h rapamycin exposure and cells harvested
at the indicated time points. For the RNA-seq experiments,
emetine (SIGMA) was added at 50 ng/ml after 72 h during
4 h to avoid long-term effects and all cells (± rapamycin, ±
emetine) were harvested at the same time.
HEK 293T cells shControl or shUPF1 were generated
employing pRS vector against humanUPF1 (RENT1) gene
or Control (OriGene, TR308482) and sub-cloning it with its
U6 promoter in pLVTHM (Tronolab) between EcoRI and
MluI sites. siRNA against 4EBP1 and 4EBP2 were trans-
fected employing Dharmafect according to manufacturer’s
instructions.
Immunofluorescence
HEK 293 T cells were seeded at low density on coverslips
overnight. Cells were treated as described above, fixed with
3.2% paraformaldehyde for 15 min at room temperature
and permeabilizedwith 0.1%TritonX-100 in PBS for 3min.
After blocking in 1% BSA + PBS 1h at room temperature
they were incubated with eIF4E-FITC primary conjugated
antibody (Santa Cruz Biotechnology) overnight at 4◦C and
washed. After washing three times with 0.02% tween PBS,
coverslips were mounted using DAPI-mounting media.
Microscopy and quantification
Immunofluorescence was performed using a LeicaDM2700
white field microscope at magnification 63X (oil immersion
objective). Quantification of fluorescence was performed
using ImageJ.
Cell fractionation and polyribosome extraction
Cells were incubated in the presence of 100 g/ml cyclo-
heximide 10 min at 37◦C, 5%CO2 prior harvesting. Cell ly-
sis was performed in 0.5% NP40, 20 mM Tris–HCl pH 7.5,
100 mMKCl and 10 mMMgCl2. Lysates were passed three
times through a 23G needle and incubated on ice 7min. Ex-
tracts were then centrifuged at 10K rpm at 4◦C 7 min. Cy-
tosolic extracts were laid on 15–45% sucrose gradients pre-
pared in 20 mMTris–HCl pH 7.5, 100 mMKCl and 10 mM
MgCl2 using a Gradient Station Master (Biocomp). Gradi-
ents were ultracentrifuged at 40K rpm 4◦C for 1 h 20 min
using SW41 rotor in a Beckman Ultracentrifuge. Polyribo-
some monitoring and extraction of discrete complexes were
conducted using a Gradient Station Master (Biocomp).
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Western blotting
Cell extracts were prepared in Lysis Buffer as described
above. For 4E-BP and P-4E-BP blots, cell extracts were re-
solved in 12% bis/acrylamide gels. For CBP80/eIF4E blots,
extracts were resolved in 10%Bis/acrylamide gels. Antibod-
ies used were: Phospho-S6 Ribosomal Protein (D57.2.2E,
Cell Signaling) 4E-BP1 (53H11, Cell Signaling), CBP80
E-7 (Santa Cruz Biotech), iEF4E FL-217 (Santa Cruz
Biotech), p-4E-BP1/2/3 (Thr 45)-R (Santa Cruz Biotech)
and U2AF65 MC3 (Santa Cruz Biotech).
Cap binding experiments
Cells were stimulated with rapamycin for 24 h and extracts
prepared in lysis buffer as described above. Oligo dT cel-
lulose (Ambion) was resuspended in lysis buffer twice be-
fore incubating it in the presence of cell extracts on a ro-
tating wheel at 4◦C during 2 h. Cellulose-bound extracts
were washed five times. RNAse treatment was done using
1/100 RNAse A/T1 cocktail (Ambion) at 37◦C during 13
min shaking. Extracts were washed once more and cellu-
lose was pelleted and resuspended in lysis buffer, boiled and
loaded onto bis/acrylamide gels for CBP80/eIF4E blotting.
Luciferase assays
HEK 293 T cells were starved for 24 h in the absence of
glutamine and then co-transfected with a normalizer fire-
fly luciferase vector (pGL3, Promega) and pCI-Renilla/-
globin wt (WT) or NS39 (MUT) kindly gifted by Prof.
A.E. Kulozik (24). Transfected cells were then treated with
vehicle (Control), 22 nM of rapamycin (Rapa) or Eme-
tine and chemiluminiscence was measured using the Dual-
Luciferase Reporter (DLR) Assay (Promega) following
manufacturer’s instructions.
RT-PCR and real-time PCR (qPCR)
Total cytoplasmic RNA and polyribosome-bound RNA
was extracted using TRIzol LS following manufacturer’s
instructions. In the case of polyribosomal-bound RNA,
RNA was extracted from discrete polyribosome fractions
and then pooled prior to reverse transcription with ran-
dom hexamers (Thermo Fisher Scientific) following man-
ufacturer’s instructions. For actinomycin D experiments,
oligodT primers were used in reverse transcription. PCR
was performed using Taq Titanium (Clontech). In the case
of total to polyribosome comparisons of CCAR1 the rate
of inclusion was calculated using the following formula
%inclusion = included/(skipped + included) in nmol as
determined using an Agilent 2001 Bioanalyzer. Statistics
were done using a Mann–Whitney one tailed U-test. For
qPCRexperiments, SybrGreen qPCR for−PTCand+PTC
was done using primers described previously in (25). Our
primers were designed using the Universal Probe Library
System Software (Roche) and blasted in UCSC Genome
Browser tool In silico PCR to hg19 assembly:
SRSF6 All FOR: tgg aag cag atc cag gtc tc
SRSF6 All REV: gcg act ttt tga gat act tcg ag
CCAR1 All FOR: CAA AAA GAA GAA CAG AAG
GAG TTA GAG
CCAR1 All REV: TCG TCT TCA GAT TTC CTA TCA
TCA
CCAR1 −PTC FOR: AAC CCT CTC CCG AGG ATA
CA
CCAR1 −PTC REV: TCA TCC TTC TCT TCT TCA
TCC TG
CCAR1 +PTC FOR: TGG ACC AGA CCC AGA AAA
AG
CCAR1 +PTC REV: TTC TTC ATC CAT TGT GTG C.
Levels of each of each isoform (‘−PTC’ or ‘+PTC’) were
normalized to total transcript levels (‘All’) which accounts
for the total gene expression of each gene and analyzed us-
ing the DDCt method. Total levels of transcript were nor-
malized against SDHA. Statistics were done using a two-
tailed t-test and calculated as fold rapamycin-treated over
control.
Primers employed in the RNA-seq validations are listed
in Supplementary Table S1.
RNA-seq
RNA was extracted from cytoplasmic extracts employ-
ing TRIzol LS following manufacturer’s instructions, and
re-purified and DNAse treated employing miRNeasy Mi-
cro Kit (Qiagen) following manufacturer’s instructions. Li-
braries were done employing TruSeq Stranded mRNA Li-
brary Prep Kit (Illumina) following manufacturer’s instruc-
tions. RNA-seq was performed on a HiSeq 4000 (UCSF)
and sequencing was performed employing 100 bp paired-
end reads, generating a minimum of 37M reads per sam-
ple (Supplementary Table S2). Reads were mapped to the
genome (hg19) using STAR v2.5.1b (26). An expanded
transcript annotation was generated using StringTie v1.2.3
(27) withGENCODEv19 as a reference annotation, and al-
ternative splicing events were identified and quantified us-
ing SplAdder v1.0.0 (28). Paired differential splicing tests
were performed using rMATS-STAT (29) with thresholds
of  ≥ 0.1,  ≥ 0.05 and  > 0, and the resulting
p-values were corrected for multiple hypothesis testing us-
ing the method of Benjamini and Hochberg (30). Differen-
tial gene expression analysis was conducted using DESeq2
(31). Additional data manipulation and visualization was
performed using custom R and Python scripts, and BED-
Tools v2.25 (32). Visualization of specific alternative events
was performed using Sashimi plots (33). Gene set enrich-
ment analysis was performed using Enrichr (34–37).
RESULTS
Rapamycin modulates levels of NMD mRNA isoforms
Given that mTORC1 interacts with splicing factors and
modulates their activity (22,38) we performed RNA-seq on
cytoplasmic extracts from HEK 293T cells treated with ra-
pamycin or vehicle, in order to characterize the genome-
wide impact of mTORC1 in alternative splicing (AS). As
expected, the phosphorylation of the ribosomal protein S6
(P-S6K) diminished when rapamycin was present in the
medium (Supplementary Figure S1A). We used SplAdder
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(28) to identify and quantify alternative splicing events, and
performed paired differential testing using rMATS-STAT
(29) to identify events modulated by rapamycin (Supple-
mentary Tables S3–S11). Our data revealed an extensive
rapamycin-dependent alternative splicing program span-
ning much of the diversity of event types with noticeable
higher fractions of skipped exons and retained introns (Fig-
ure 1A). Moreover, Gene Set Enrichment Analysis (GSEA)
of differentially spliced genes (34–36) revealed ontologies
associated with splicing and RNA processing among the
most significantly enriched categories (Supplementary Ta-
bles S12 and S13).
The enrichment of RNA processing pathways in
rapamycin-sensitive differentially spliced transcripts
together with the high abundance of regulated intron reten-
tion events (Figure 1A, Supplementary Tables S12 and S13)
suggested that rapamycin may modulate NMD activity
(3,25). To test our hypothesis that mTORC1 inhibition
alters NMD and to understand which of these AS events
may be linked to RNA surveillance we employed emetine,
in order to seek for overlap with rapamycin-sensitive events
similarly to (39). Emetine is a translational inhibitor, and
thus increases the half-life of NMD-sensitive mRNAs
given the dependency of NMD on ribosomal scanning
(9,23). Intriguingly, alternative events perturbed by emetine
were enriched in similar categories and the overlap between
differential events in the rapamycin and the emetine con-
dition is significant (hypergeometric test, P-value < 9e−56
for  ≥ 0.1, FDR ≤ 0.05, P-value < 2e−167 for  ≥
0.05, FDR ≤ 0.05, P-value < 3e−321 for  > 0, FDR ≤
0.05). Of these events, we find the majority to be changing
in the same direction (e.g. 144 of 220 common events for
 > 0.1, FDR < 0.05) (Figure 1B). While this supports
a broad notion of a common post-transcriptional response
to translation inhibitors, it raises the issue of explaining the
behavior of the significant number of events (e.g. 76 of 220
common events for  > 0.1, FDR < 0.05) changing in
opposite directions.
To examine the data specifically for evidence of NMD
perturbation, we restricted our analysis to events over-
lapping transcripts already annotated as NMD targets in
GENECODE v19. Moreover, we further restricted the set
of events to those behaving as expected in the presence of
emetine (i.e. the NMD-sensitive form must increase). In ex-
amining the behavior of these isoforms in the presence of ra-
pamycin, we found that, of those that significantly changed,
at every  threshold tested, more than half exhibited be-
havior opposite to their emetine-dependent behavior (Fig-
ure 1C and Supplementary Tables S14 to S16). We also
examined overall gene expression level employing DESeq2
(31) and performed GSEA, which revealed splicing-related
terms to be among the most significant in both control
versus rapamycin, and control versus emetine comparisons
(Supplementary Tables S17 to S20). These results suggested
the intriguing idea that rapamycin may conditionally en-
hance the efficiency of NMD.
To explore the possibility of rapamycin-dependent NMD
augmentation, we began by confirming the behaviour of
several emetine- and rapamycin-sensitive mRNAs exhibit-
ing this pattern in the RNA-seq data (Figure 1D, E and
Supplementary Figure S1B). We chose three candidates
(CCAR1,HNRNPDL and SRSF6 genes) for RT-PCR vali-
dation, each with different modalities of AS-NMD: a) skip-
ping of exon 13 from CCAR1 mRNA which leads to a
frameshift that triggers NMD b) inclusion of exon 8 in the
HNRNPDL mRNA introduces a PTC that induces NMD
and c) inclusion of exon 3 in the SRSF6 mRNA which in-
troduces a PTC and inducesNMD. Importantly, these three
genes encode for functionally different proteins, and thus
are likely to be regulated by different processes: CCAR1
(Cell Division Cycle And Apoptosis Regulator 1) encodes
for a protein that acts as a signal transductor, HNRN-
PDL (Heterogeneous Nuclear Ribonucleoprotein D Like)
encodes for an RNA binding protein that complexes with
heterogeneous nuclear RNA and SRSF6 (Serine/Arginine-
Rich Splicing Factor 6) encodes one member of the SR pro-
tein family and is a splicing regulator. Figure 1D depicts the
Sashimi plots (33) representing the alternative splicing pat-
tern triggered by rapamycin and emetine compared to con-
trol, demonstrating the effects of rapamycin on the NMD-
sensitive isoform according to our RNA-seq data. Figure
1E shows representative gels demonstrating that rapamycin
was able to diminish the levels of the NMD-sensitive can-
didates (compare lanes 1 and 2, 5 and 6, and 9 and 10), an
effect that was abrogated when emetine was added (com-
pare lanes 3 and 4, 7 and 8, and 11 and 12). These data val-
idate the RNA-seq results and bolster the hypothesis that
rapamycin-treatment may augment NMD.
Depletion of PTC-containing mRNA isoforms by rapamycin
is dose dependent
The RNA-seq analysis described above revealed a sub-
set of isoforms that exhibited opposite expression patterns
in rapamycin-treated and emetine-treated cells. These data
suggest the intriguing hypothesis that rapamycin may in-
crease nonsense mediated decay. To assess the effects of dif-
ferent doses of rapamycin on NMD substrates we assayed
the abundance of NMD sensitive and insensitive mRNA
isoforms over a broad rapamycin concentration range by
RT-qPCR in HEK 293T cells. If the effects we observed in
Figure 1 are dependent on rapamycin, our expectation was
that decreasing the concentration of rapamycin may have
an effect on the abundance of PTC-containing mRNAs ac-
cordingly. Following our starvation protocol as in Figure
1, we assayed the phosphorylation of another rapamycin
downstream target, 4EBP (17). As expected, phosphoryla-
tion of 4EBP decreases with increasing rapamycin concen-
trations, suggesting that the activity of the mTORC1 path-
way is being modulated in a dose-dependent manner (Fig-
ure 2A). We firstly set out to test the qPCR quantification
of PTC-containing and non-PTC mRNA levels of a well-
characterised NMD-candidate, SRSF6 gene, according to
Laureau et al. (25) in our RNA-seq datasets, which showed
a significant decrease in the PTC-containing isoform upon
rapamycin treatment (Supplementary Figure S2). We then
assayed the expression of PTC-containing (PTC+) and non-
PTC-containing (PTC-) isoforms for SRSF6 and CCAR1
genes employing a range of rapamycin concentrations. Fig-
ures 2B and 2C show that PTC-containing isoforms of
SRSF6 andCCAR1 genes, respectively, significantly dimin-
ish with increasing concentrations of rapamycin. This de-
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Figure 1. Genome-wide effects of rapamycin in alternative splicing and NMD-sensitive isoforms. (A) Alternative splicing events predominantly regulated
by emetine and rapamycin ( ≥ 0.1, FDR≤ 0.05) in HEK 293T cells. RI: retained introns; SE: skipped exons; Alt 5′ss: Alternative 5′ Splice Site; Alt 3′ss:
Alternative 3′ Splice Site; MES: Multiple Exon Skipping; MEE: Mutually Exclusive Exons. (B) Heatmap depicting the directionality of those alternative
splicing events showing significant changes by rapamycin or emetine treatment compared to control. (C) Bar graph showing the fraction of events with
NMD annotation triggered by rapamycin (All, dark grey) and those that showed opposite behavior to emetine (orange). (D) Sashimi plots representing
the mapped reads of our triplicate RNA-seq samples for SRSF6, CCAR1 and hnRNPDL genes in Control (orange), Rapamycin (red) and Emetine (blue).
The Y-axis units are arbitrary, as plots were normalised by sample in the event window. Schematics of the events and the position of primers are depicted
underneath. (E) Representative gel of RT-PCR analysis of SRSF6, CCAR1 and hnRNPDL PTC-containing (red asterisk) and non-PTC mRNAs for each
of the genes.
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Figure 2. PTC-containing mRNA isoforms respond to rapamycin in a
dose-dependent manner. (A) Western blot analysis of 4EBP and U2AF65
(upper and lower panel) from HEK 293T cell lysates treated with de-
creasing concentrations of rapamycin. (B) Relative RT-qPCR analysis of
SRSF6 mRNA isoform (−/+ PTC) levels (normalized to total SRSF6
levels, paired two-tailed t-test, n = 5) from cytoplasmic extracts of HEK
293T cells treated with rapamycin as described above. Note: the data
is paired and represented as mean + standard deviation of the mean.
(C) RT-qPCR analysis of CCAR1 mRNA isoforms (−/+, normalized
to total CCAR1 mRNA levels, paired two-tailed t-test, n = 5) as de-
scribed above. (D) Schematic for the luciferase reporter (24) employed
in 1E. (E) Luciferase assays for rapamycin effects on an NMD-reporter.
Y axis represents the ratio of Relative Luminescence Units of the nor-
malized renilla NMD-reporter compared to the normalized WT-reporter
(RLUMUT/WT).X axis represents the different treatments: vehicle (Con-
trol), 22 nM rapamycin (Rapa) or emetine (Emetine) (n = 3, 2 biological
replicates/sample, Mann–Whitney two-tailed U-test).
crease is statistically significant at the highest doses, 22nM
and 2.2nM of rapamycin. We also assayed the levels of total
gene expression for SRSF6 and CCAR1 employing primers
to amplify constitutive exons in each gene and using SDHA
for normalization as described in (25). Our data for SRSF6
and CCAR1 suggest that rapamycin causes an overall in-
crease in the total mRNA expression of both genes (Sup-
plementary Figure S3).
To determine the effects of rapamycin in exogenous PTC-
containing transcripts we employed a previously developed
and validated NMD reporter (24). We co-transfected HEK
293T cells with a reporter vector containing a wild type––-
globin open reading frame (WT) or an NMD-triggering
mutation-globin (MUT) fused to a renilla luciferase gene
(schematics in Figure 2D) together with a normalizer firefly
luciferase vector. Transfected cells were then treated with
vehicle (Control), 22 nM of rapamycin (Rapa) or emetine
and chemiluminiscence wasmeasured. Figure 2E shows our
results as Relative Luminescence Units of the normalized
renilla NMD-reporter compared to the normalized WT-
reporter (RLUMUT/WT) as in (24). Our data indicate that
the expression of the NMD reporter was significantly di-
minished (Mann–Whitney two-tailedU-test) in cells treated
with rapamycin compared to vehicle (compare Rapa to
Control). As expected, emetine treatment increased the sta-
bility of the NMD reporter. Taken together, our data sup-
port a mechanism for rapamycin triggering depletion of
PTC-containing mRNAs.
Effects of rapamycin on SRSF6 PTC-containing mRNA iso-
forms require UPF1 and 4EBPs
The previous experiments suggested that rapamycin aug-
ments NMD activity and decreases levels of PTC-
containing isoforms in HEK cells. In order to confirm that
the observed change in the ratio of PTC-containing/non-
PTC isoforms is due toRNAdecay and notmerelyAS regu-
lation, we assayed the half-life of PTC-containing and non-
PTC isoforms of SRSF6 in a rapamycin dependent manner
using RT-qPCR. Figure 3A shows that endogenous SRSF6
PTC-containing isoform displayed accelerated decay kinet-
ics in rapamycin-treated cells as compared to the non-PTC
isoform, suggestive of an increased rate of NMD rather
than regulation of AS.
To test the direct role of NMD machinery in rapamycin
effects, we compared the levels of PTC-containing SRSF6
mRNA isoforms in UPF1-depleted HEK cells treated with
or without rapamycin. Depletion of UPF1 inhibits NMD
in a variety of model systems (39,40). We generated sta-
bly transduced HEK cell lines with an inducible Tet-On
shRNA against UPF1 or a scramble control (41) (Figure
3B). As previously observed, rapamycin stimulation de-
creased the levels of PTC-containing isoforms of endoge-
nous SRSF6 in control cells. However, this effect was atten-
uated in the UPF1 depleted cells (Figure 3C). These data
demonstrate that the depletion of PTC-containing isoforms
by rapamycin is dependent onUPF1 and supports our find-
ings that rapamycin enhances NMD.
Given that rapamycin effects on translation rely on 4EBP
modulation, we predicted that depletion of 4EBPs should
attenuate the effect of rapamycin on NMD. To test this
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Figure 3. Rapamycin alters the stability of PTC-containing isoforms and its effects are UPF1- and 4EBP-dependent. (A) Relative RT-qPCR analysis of
constitutive SRSF6, SRSF6 non-PTC isoforms (SRSF6 −PTC) and PTC-containing (SRSF6 +PTC), after rapamycin treatment and translational arrest
with actinomycin D to measure mRNA half-life (n = 5) in HEK 293T cells. (B) Representative western blot of the inducible Tet-on shUPF1 cell line
and schematic of the Tet-on system. C. RT-qPCR analysis of SRSF6 PTC+ mRNA isoforms in control or UPF1-depleted cells treated with or without
rapamycin (n = 4; ***P-value < 0.001, ns: non-significant). (D) Western blot analysis of 4EBP and GAPDH in cells transfected with siRNAs against
4EBP1-2 or control and stimulated with/without rapamycin. (E) RT-qPCR analysis of SRSF6 PTC-containing mRNA in cells from D (n= 3). C: Control
(black bars), R: Rapamycin (white bars).
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hypothesis, we transfected HEK 293T cells with a com-
bination of siRNAs against 4EBP1 and 4EBP2 or scram-
bled control and treated these cells with rapamycin. As ex-
pected, rapamycin treatment decreased the phosphoryla-
tion of 4EBP relative to control cells (Figure 3D, compare
lanes 1–3 with 7–9). Additionally, siRNAs against 4EBP1
and 4EBP2 substantially reduced 4EBP protein levels rel-
ative to control siRNAs (Figure 3D, compare lanes 1–3
and 7–9 with lanes 4–6 and 10–12). RT-qPCR revealed that
rapamycin significantly decreased SRSF6 PTC-containing
mRNA isoforms relative to total SRSF6 mRNA in cells
transfected with control siRNA, but had no effect on levels
of 4EBP-depleted cells (Figure 3E). Taken together, these
data demonstrate that rapamycin decreases levels of PTC-
containing isoforms in a UPF1- and 4EBP-dependent man-
ner, suggesting a role for rapamycin in augmentation of
NMD through 4EBP-mediated modulation of translation.
Rapamycin decreases levels of PTC-containing isoforms
bound to polyribosomes
NMD can happen not only during pioneer translation but
also during steady translation, given that eIF4E-bound
mRNAs are substrates of NMD (42). Moreover, Du-
rand et al. demonstrated that eIF4F-bound transcripts
are susceptible to NMD (43). A prediction from these
experiments is that NMD efficiency of polyribosome-
associated mRNAs may be dynamically regulated. Given
that NMD in mammals is translation-dependent (9,44–
46), that rapamycin inhibits eIF4E-dependent translation
of capped mRNAs, and that rapamycin effects are depen-
dent on the presence of 4EBPs (Figure 3E), we hypothe-
sized that rapamycin-treatment might enhance the decay
of polyribosome-bound PTC-containing transcripts.We in-
vestigated this hypothesis in cells treated with or with-
out 22nM rapamycin. As expected, rapamycin-treatment
increased the electrophoretic mobility of 4EBP on SDS-
PAGE relative to control cells (Figure 4A), indicative of
4EBP hypophosphorylation. We then isolated polyribo-
somes from control or rapamycin treated cells. We ob-
served that rapamycin treated cells showed the distinc-
tive characteristics of global translational inhibition when
compared to control cells: an increase in the monosomal
fraction (80S, peak) and a decrease of the polyribosome
fractions (Figure 4B shows representative polyribosome
profiles of rapamycin versus control cells). We then ana-
lyzed the presence of PTC-containing and non-PTC iso-
forms in the polyribosomal fractions, excluding the 80S
monosomal peak. In control cells we observed an en-
richment of the SRSF6 PTC-containing isoform in the
polyribosome-associated mRNA fraction as compared to
total cytoplasmic mRNAs (Figure 4C, compare lanes 1
and 2). Rapamycin-treatment dramatically reduced levels
of the PTC-containing SRSF6 isoform in polyribosome-
associated mRNA fractions (Figure 4C, compare lanes 2
and 4). To rule out alternative splicing as the underlying
cause of PTC-containing isoform depletion from polyribo-
somes in rapamycin-treated cells, we stimulated cells with
both rapamycin and afterwards with the translation elon-
gation inhibitor emetine. We expected that if rapamycin
effects were splicing dependent, then emetine treatment
would not alter the levels of PTC-containing isoforms ob-
served in polyribosomal-bound fractions between control
and rapamycin treated cells. As expected, we observed that
the effect of rapamycin was attenuated by emetine (compare
lanes 6 and 8 in Figure 4C). Taken together these data sug-
gest that rapamycin alters the stability of PTC-containing
isoforms in polyribosome complexes rather than the AS of
their pre-mRNA.
We further assayed the abundance of PTC-containing
and non-PTC isoforms of SRSF6 and CCAR1 in total
and polyribosome-bound mRNA fractions at 7 h post-
rapamycin stimulation. Rapamycin significantly diminished
the presence of the PTC-containing isoforms in polyri-
bosomal fractions of both SRSF6 and CCAR1 (Supple-
mentary Figure S4) genes whereas the effects were not
detectable when comparing the total pool of mRNAs.
Together these data suggest that rapamycin diminishes
the abundance of PTC-containing transcripts through a
translation-dependent mechanism.
Previous studies demonstrated that rapamycin treat-
ment induces nuclear accumulation of eIF4E through de-
phosphorylation and de-repression of 4EBP (17,21). We
confirmed these data in HEK 293 T cells: upon glutamine
starvation we observed rapamycin-dependent modest nu-
clear accumulation of eIF4E whereas it localized predom-
inantly to the cytoplasm in control cells. In contrast, in
rapamycin-treated cells we observed strong accumulation of
eIF4E in the nucleus (Supplementary Figure S5). Our pre-
vious results suggest a role for rapamycin in the degrada-
tion of PTC-containing isoforms that is 4EBP- dependent
and correlates with polyribosome binding. Given that ra-
pamycin modulates translation of both eIF4E- and CBC-
bound transcripts (21,22), and because rapamycin treat-
ment caused nuclear sequestration of eIF4E in our ex-
periments, we hypothesized that exchange of cap binding
proteins on mRNAs may also be dynamically modulated
by rapamycin. We thus purified cytoplasmic mRNPs from
control or rapamycin-treated cells and assayed eIF4E and
CBP80 association in an RNA-dependent manner. Figure
4D shows a representative western blot of eIF4E, CBP80,
SRSF1 and U2AF65 in whole cell extracts (lanes 1 and 2)
and RNase-treated (lanes 3 and 4) or untreated (lanes 5
and 6) eluates from oligo dT cellulose affinity chromatog-
raphy. We observed that rapamycin-treatment increased
the electrophoretic mobility of 4EBP, consistent with de-
phosphorylation. With the exception of U2AF65, which
binds directly to oligo dT cellulose, SRSF1, CBP80 and
eIF4E were all RNase-sensitive (lanes 3–4), suggesting that
their binding to oligo dT cellulose is RNA-dependent. Un-
like SRSF1 protein, which bound to polyA-mRNAs equally
in the presence or absence of rapamycin, CBP80 and eIF4E
mRNPs levels were inversely correlated (lanes 5–6). Treat-
ment with rapamycin resulted in a decrease of eIF4E asso-
ciation with polyadenylated mRNPs and a modest but re-
producible increase in CBP80 association.
Taken together, our data suggest that rapamycin-
treatment impairs the normal exchange of CBP80 with
eIF4E on cytoplasmic mRNPs, rendering them more sus-
ceptible to nonsense mediated decay and subsequent in-
creased degradation of PTC-containing mRNAs.
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Figure 4. Rapamycin alters the levels of polyribosome associated PTC-containing mRNA isoforms. (A) Representative western blot of 4EBP levels from
control or rapamycin-treated HEK 293T cells. (B) Representative 260 nm UV absorbance across 15–45% sucrose gradients of cytoplasmic extracts from
cells treated with or without rapamycin (n = 3). (C) Endpoint RT-PCR analysis of PTC+/− SRSF6 mRNA isoforms in either cytoplasmic (T) or polyri-
bosome associated (P) extracts treated with or without rapamycin and emetine. (D) Western blot analysis of proteins co-purified with poly A+ RNA from
cytoplasmic extracts of control or rapamycin-treated cells.
DISCUSSION
Our data demonstrate a complex relationship between ra-
pamycin, alternative splicing and NMD. We find that ra-
pamycin treatment can increase the abundance of PTC-
containing transcripts, but also diminish expression of a
significant number of putative NMD substrates. We pro-
pose at least two mechanisms that can account for these
observations (Figure 5). One possibility is that rapamycin-
treatment modulates the exchange of CBC and eIF4E on
the caps of cytoplasmic mRNAs. The increased association
of CBCwith cytoplasmic transcripts observed in Figure 4D
may promote decay of PTC-containing transcripts. By con-
trast, it is possible that rapamycin may influence the compe-
tition of transcripts for ribosomes as previously described
in budding yeast (47) and favor translation of canonical
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Figure 5. Our proposed models for rapamycin effects on NMD. Blue
hexagons: cap, red hexagons: PTC. (A) Rapamycin decreases association
of eIF4E rendering higher association of CBC binding and increased
degradation of CBC-bound NMD-transcripts. (B) Rapamycin-dependent
changes in translational efficiency for different subsets of transcripts. Ra-
pamycin positively and negatively modulates translation of different tran-
scripts populations. In this model augmentation of NMD is coupled to
enhanced translation ofNMD-insensitive transcripts in rapamycin-treated
cells.
mRNA isoforms while NMD-sensitive transcripts are de-
graded. In this case, augmentation of NMD, as observed
for transcripts such as SRSF6 andCCAR1, would correlate
with up-regulated translation in the presence of rapamycin.
In mammalian cells, nonsense mediated decays occurs
predominantly during a pioneering round of mRNA trans-
lation (48). The ribonucleoprotein context of this initial
round of translation is characterized by the presence of
EJC proteins, PABPN1 and the CBC (5,6). Translating ri-
bosomes remodel the mRNP by displacing EJC factors
(8,9,49). Our work demonstrates that rapamycin influences
the composition of cytoplasmic mRNPs by increasing the
association of CBC with cytoplasmic polyadenylated tran-
scripts while concomitantly decreasing eIF4E association
(Figure 4D). These findings are consistent with previous
work showing that the mTOR inhibitors decrease the asso-
ciation of the eIF4F components eIF4A and eIF4G with
immobilized m7G cap in mammalian cells (50). Because
CBC stimulates NMD activity (18) it may be possible that
elevated CBC levels on cytoplasmic mRNPs could augment
NMD. Thus, rapamycin could promote a pioneer-like con-
text for some cytoplasmic mRNPs by maintaining CBC as-
sociation.
NMD is dependent upon translation and can occur in as-
sociation with polyribosomes (44,51). In yeast, rapamycin
has complex impacts on the association of mRNAs with
polyribosomes (47). Whereas the polyribosome association
of a majority of transcripts is only modestly affected by ra-
pamycin, there is a significant fraction exhibiting increased
or decreased association. In many cases these changes are
positively correlated with changes in steady state mRNA
levels, suggesting coupling of transcriptional and transla-
tional responses to rapamycin (47). Our data cannot exclude
the possibility that augmentation of NMD by rapamycin
may occur because transcripts from specific genes (such as
SRSF6 or CCAR1) are preferentially associated to polyri-
bosomes in rapamycin-treated cells relative to control. Like-
wise, mRNA isoforms with reduced NMD efficiency may
correspond to transcripts that are translationally compro-
mised by rapamycin-treatment. These data could be con-
sistent with a model in which rapamycin influences com-
petition between transcripts for the translation machinery.
A similar trans-competition control mechanism has been
described for rapamycin-dependent splicing regulation in
yeast (52).
Rapamycin’s effects on NMD may also rely on post-
translational modifications (such as phosphorylation) of
NMD factors in addition to augmentation of CBC-binding
to mRNPs (Figure 4D). Work by Pal et al. has shown
that phosphorylation of UPF1 is sensitive to rapamycin
(53); however the effect of lowered UPF1 phosphorylation
on PTC-containing mRNAs was not tested. Moreover, al-
though rapamycin concentration was similar to our work-
ing dose (25nM and 22nM, respectively), cells were only
exposed for a short time (30min vs 72h in our case). Sim-
ilarly, Yamashita et al. (54) showed no effect of rapamycin
on a -globin reporter but exposure time (2 h) and doses (60
nM and 600 nM) were significantly different to those em-
ployed in our system. Importantly, our RNA-seq revealed
that the mRNA of only one NMD factor, SMG6 gene, was
up-regulated by exposure to rapamycin. We do not exclude
the possibility that prolonged exposure to rapamycin may
result in phosphorylation changes in some of NMD factors
(or their regulators), and that these, in addition to mRNP
remodeling, may contribute to the overall effect that we ob-
serve in our system.
We propose that augmentation of NMD by rapamycin
could have important implications for cell biology and phys-
iology. Given that rapamycin increases lifespan in a wide
variety of model systems, including mammals (19,20), it
will be important to determine how rapamycin modulates
NMD efficiency and if this may affect ageing-related pro-
cesses, for example, its potential role in telomere protection
given the presence of NMD factors that protect chromo-
somes from telomere loss (55). If rapamycin does indeed
augment NMD then perhaps improved transcript surveil-
lance could facilitate degradation of potentially deleterious
mRNAs, similarly to recent work suggesting that RNA de-
cay mechanisms and ribosomes are central to degrading ox-
idized RNA (56), linked to neurodegenerative diseases (57).
We believe our study presents novel experimental evidence
for the role of rapamycin in NMD and that further explo-
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ration may give insight into RNA metabolism by extracel-
lular signals in a wide set of biological contexts.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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